This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
FDA approves controversial Alzheimer drug Aduhelm
FDA grants accelerated approval to aducanumab Biogen and Eisai to treat Alzheimer’s disease despite advisory warnings the benefit is unproven. The drug slows decline in one study but does not reverse symptoms and faces postmarket follow up.
MENTIONED IN THIS ARTICLE
Washington
Food and Drug Administration
U.S
Biogen
Japan
Eisai Co
Caleb Alexander
FDA
Institute For Clinical and Economic Review
Aducanumab
Richard Hodes
National Institute On Aging
Medicare
File Apa
Cambridge
Mass